Marco H. Hofmann

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

This study shows that DUSP4 knockdown causes cell cycle arrest and halts tumor growth in BRAF V600E mutant colorectal cancer models but does not lead to tumor regression.

This study shows that the SOS1-RAS inhibitor BI-3406 promotes β-cell proliferation and reverses diabetic hyperglycemia in mice.

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.

This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.